Biotech Stock Closing in on Human
Trials
May 17, 2019 -- InvestorsHub NewsWire -- Microcap Speculators --
Growth based biotech stocks are one of the few sectors that aren’t
negatively affected by Trump’s trade war. Below are a few to
start your research on.
One company getting closer to a human trial, Propanc
Biopharma, Inc. (USOTC:
PPCB), initiated development of a bio-analytical assay
intended to quantify the active ingredients of the company's lead
product candidate, PRP, in preparation for human trials in March
‘19. This is just one step closer for a company that has been
making steady progress over the past year or so.
The companies we’re highlighting today include:
Propanc Biopharma, Inc. (USOTC:
PPCB), Aurora Cannabis, Inc. (NYSE:
ACB), ImmunoGen, Inc. (NASDAQ:
IMGN), PDS Biotechnology Corporation (NASDAQ:
PDSB), and Advaxis, Inc. (ADXS).
Propanc Biopharma, Inc. (USOTC:
PPCB)
(Market Cap:
$3.155M;
Share Price:
$0.0078), a
clinical stage biopharmaceutical company focusing on development of
new and proprietary treatments for cancer patients suffering from
solid tumors such as pancreatic, ovarian and colorectal cancers,
was granted FDA Orphan Drug Designation status for its PRP
treatment of pancreatic cancer almost a year back. This
qualifies the company for seven-year FDA-administered market Orphan
Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs,
potential for R&D grants, waived FDA fees, protocol assistance
and possible clinical trial tax incentives if conducted in the
U.S. The company is also close to first-in-human studies.
PPCB announced that the company has appointed Dr.
Ralf Brandt to its Scientific Advisory Board (SAB). He
will provide significant translational research expertise and
clinical support advisory support services to the company's drug
development pipeline.
PPCB is developing a novel approach to prevent recurrence and
metastasis of solid tumors by using pancreatic proenzymes that
target and eradicate cancer stem cells in patients suffering from
pancreatic, ovarian and colorectal cancers.
PPCB has a growing patent portfolio that larger healthcare
companies could be very interested in. It is among many
biotech’s that could be considered a bit oversold due to current
market conditions.
________
Aurora Cannabis, Inc. (NYSE:
ACB) (Market Cap: $9.134B; Share Price:
$8.89) reported a 20% jump in quarterly net revenue
on Tuesday, as Canada's legalization of recreational cannabis late
last year boosted demand.
The Edmonton, Alberta-based company's net revenue rose to C$65.2
million ($48.44 million) from C$54.2 million ($40.27 million) in
the second quarter. ($1 = 1.3459 Canadian dollars).
________
ImmunoGen, Inc. (NASDAQ:
IMGN) (Market Cap:
$294.576M;
Share Price:
$1.97) plunged more than
30% on Wednesday after the company revealed that the U.S. Food and
Drug Administration has recommended further trials to "evaluate the
safety and efficacy" of one of its cancer-fighting
treatments. ImmunoGen said in statement that it had requested
a meeting with FDA officials to discuss the results of its Phase 3
FORWARD I trial and a potential path to registration for
mirvetuximab monotherapy - a treatment it has been developing for
patients with certain forms of ovarian cancer.
________
PDS Biotechnology Corporation (NASDAQ:
PDSB) (Market Cap: $41.288M; Share
Price: $7.72) announced a peer-reviewed publication
supporting the novel mechanisms of action of its proprietary
Versamune® platform in cancer immunotherapy. The
article “Antigen Priming with Enantiospecific Cationic Lipid
Nanoparticles Induces Potent Antitumor CTL Responses through Novel
Induction of a Type I IFN Response” was published online on
May 3, 2019 in the Journal of Immunology, and describes the way
PDS’ Versamune® platform recruits and activates killer T-cells
to recognize and effectively attack cancer cells while
simultaneously making cancer cells more susceptible to T-cell
attack. The article will appear in print in the June 2019
issue of the Journal.
________
Advaxis, Inc. (ADXS) (Market Cap: $24.178M; Share
Price: $3.02), a late-stage biotechnology
company focused on the discovery, development and commercialization
of immunotherapy products, today announced that the U.S. Food and
Drug Administration (FDA or Agency) has lifted the partial clinical
hold on AIM2CERV, the company’s Phase 3 clinical trial of
axalimogene filolisbac (AXAL) for the treatment of patients with
high-risk locally advanced cervical cancer. In its letter,
the FDA acknowledged that the company satisfactorily
addressed all hold questions.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting expects to be paid $3,000 for
the article directly from PPCB. All payments were made
directly by Propanc Biopharma, Inc. (USOTC:
PPCB) to Regal Consulting, LLC. to provide investor
relations services, of which this article is a part of. Regal
Consulting also paid one thousand dollars cash to
microcapspeculators.com to distribute this article. Regal
Consulting may have a position in the securities mentioned in this
article at the time of publication, and may increase or decrease
its position without notice. This article is based on public
information and the opinions of Regal Consulting. PPCB was given an
opportunity to edit this article. This article contains
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially
from any results predicted herein. Regal Consulting is not
registered with any financial or securities regulatory authority,
and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
SOURCE: Microcap Speculators
Propanc Biopharma (PK) (USOTC:PPCB)
Historical Stock Chart
From Dec 2024 to Jan 2025
Propanc Biopharma (PK) (USOTC:PPCB)
Historical Stock Chart
From Jan 2024 to Jan 2025
